Slide 1: Q2 2024 Earnings Call
Q2 2024 Earnings Call August 6, 2024
Slide 2: Forward Looking Statements
Forward Looking Statements Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the
Slide 3: Presenters
Jerrell Shelton Robert Stefanovich CEO - Cryoport CFO, SVP - Cryoport Mark Sawicki, Ph.D. Thomas Heinzen Chief Scientific Officer – Cryoport VP Investor Relations and and CEO - Cryoport Systems Corporate Development - Cryoport
Slide 4: Summary
Summary A leading global provider of supply chain solutions for the Life Sciences with an emphasis on cell & gene therapies. Cryoport enables manufacturers, contract manufacturers (CDMO's), contract Business description research organizations (CRO's), developers, and researchers to carry out their r
Slide 5: Cryoport, Inc. Organization
Cryoport, Inc. Organization (NASDAQ: CYRX) © 2024 CRYOPORT, INC. CONFIDENTIAL |5
Slide 6: Cryoport – Q2 2024 Snapshot
Cryoport – Q2 2024 Snapshot Performance Global Platform (2) over 50 Facilities Globally $57.6 MM $225- $235 MM $427.1 MM in 17 Countries Q2-2024 Revenue FY 2024 Updated Cash & Short-Term Revenue Guidance investments C> Supply Chain Leader Over 3,000+ Global Clients 17 +50% YoY 684 1,000+ Employees
Slide 7: Growing Cell & Gene Therapy Pipeline
Growing Cell & Gene Therapy Pipeline ✓684 clinical trials (net) in aggregate Clinical Trials Supported by Trial ✓ 76 Phase III trials in the Americas, EMEA and APAC Phase as of 6/30/24 Increased by 16 trials (net) over Q2 2023 Source: Company materials cross-referenced to clinical trial information
Slide 8: CGT Clinical Trials by Phase and Region
CGT Clinical Trials by Phase and Region © 2024 CRYOPORT, INC. CONFIDENTIAL |8
Slide 9: Cryoport Commercial Support – Now 17
Cryoport Commercial Support – Now 17 AKUUGO® © 2024 CRYOPORT, INC. 9
Slide 10: A Unified Network Supporting the Life Sciences
A Unified Network Supporting the Life Sciences 17 countries > 50 locations US IE Brentwood, Tennessee Dublin Irvine, California PL Morris Plains, New Jersey Warsaw Houston, Texas Ball Ground, Georgia PH New Prague, Minnesota Manila Valley Stream, New York KR Huntington Beach, California Seoul Chicag
Slide 11: Cryoport’s Services Offering
Cryoport’s Services Offering © 2024 CRYOPORT, INC. CONFIDENTIAL | 11
Slide 12: Cryoport Revenue Drivers
Cryoport Revenue Drivers Services revenue 66% of total revenue in Q2 2024 Q2 2023 Revenue Q2 2024 Revenue Product Product 38% 34% Services Services 62% 66% © 2024 CRYOPORT, INC. CONFIDENTIAL | 12
Slide 13: Cryoport Revenue Drivers
Cryoport Revenue Drivers BioStorage/BioServices Commercial Cell and Gene Revenue Therapy Revenue ($ in millions) ($ in millions) $6.5 $3.5 $4.3 $3.2 Q2 2023 Q2 2024 Q2 2023 Q2 2024 © 2024 CRYOPORT, INC. CONFIDENTIAL | 13
Slide 14: Commercial Revenue Growth
Commercial Revenue Growth © 2024 CRYOPORT, INC. CONFIDENTIAL | 14
Slide 15: © 2024 CRYOPORT, INC. CONFIDENTIAL
© 2024 CRYOPORT, INC. CONFIDENTIAL | 15
Slide 16: Revenue by Type
Revenue by Type © 2024 CRYOPORT, INC. CONFIDENTIAL | 16
Slide 17: Statement of Operations
Statement of Operations © 2024 CRYOPORT, INC. CONFIDENTIAL | 17
Slide 18: Adjusted EBITDA
Adjusted EBITDA © 2024 CRYOPORT, INC. CONFIDENTIAL | 18
Slide 19: Upcoming Investor Conferences
Upcoming Investor Conferences Host Conference Date Location Annual MedTech & Needham August 12-13, 2024 Virtual Diagnostics Conference Annual MedTech, Tools and UBS August 13-14, 2024 Dana Point, CA Genomics Summit Healthcare Services Jefferies August 28-29, 2024 Nashville Bus Tour Global Healthcare
Slide 20: Cryoport
O Cryoport Enabling the Future of Medicine . " , Me iS le — — ——